Sionna Therapeutics (SION) Liabilities and Shareholders Equity (2024 - 2026)

Sionna Therapeutics has disclosed Liabilities and Shareholders Equity across 3 years of filings, most recently posting $305.0 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $305.0 million, down 17.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 138.07% YoY), and the FY2025 annual result was $326.0 million, up 75.48% from the prior year.
• Liabilities and Shareholders Equity came in at $305.0 million for Q1 2026 at Sionna Therapeutics, down from $326.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $369.7 million in Q1 2025 to a low of $185.8 million in Q4 2024.
• The 3-year median for Liabilities and Shareholders Equity is $332.6 million (2025), against an average of $313.0 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 75.48% in 2025 and retreated 17.48% in 2026, its largest moves.
• Sionna Therapeutics' Liabilities and Shareholders Equity stood at $185.8 million in 2024, then jumped by 75.48% to $326.0 million in 2025, then decreased by 6.42% to $305.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $305.0 million (Q1 2026), $326.0 million (Q4 2025), and $339.3 million (Q3 2025), per Business Quant data.